Syros Pharmaceuticals Inc (SYRS) Expected to Post Quarterly Sales of $400,000.00
Brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post sales of $400,000.00 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest sales estimate coming in at $410,000.00 and the lowest estimate coming in at $400,000.00. The firm is expected to report its next earnings report on Monday, March 11th.
On average, analysts expect that Syros Pharmaceuticals will report full year sales of $1.58 million for the current financial year, with estimates ranging from $1.56 million to $1.60 million. For the next financial year, analysts forecast that the company will post sales of $1.94 million, with estimates ranging from $1.60 million to $2.50 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The firm had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million.
Several institutional investors and hedge funds have recently bought and sold shares of SYRS. Acadian Asset Management LLC increased its stake in Syros Pharmaceuticals by 7,084.0% during the second quarter. Acadian Asset Management LLC now owns 28,233 shares of the company’s stock valued at $288,000 after purchasing an additional 27,840 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $611,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Syros Pharmaceuticals by 79.1% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,661 shares of the company’s stock worth $1,048,000 after purchasing an additional 45,350 shares during the period. Alps Advisors Inc. bought a new stake in shares of Syros Pharmaceuticals in the second quarter valued at approximately $483,000. Finally, Rhumbline Advisers raised its stake in shares of Syros Pharmaceuticals by 87.6% in the second quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after purchasing an additional 10,494 shares in the last quarter. Institutional investors own 61.26% of the company’s stock.
Shares of SYRS traded down $0.51 during trading hours on Friday, hitting $7.00. The company had a trading volume of 150,607 shares, compared to its average volume of 84,765. The company has a market cap of $229.19 million, a P/E ratio of -3.29 and a beta of 0.80. Syros Pharmaceuticals has a 52-week low of $6.25 and a 52-week high of $14.90.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Story: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.